



From the Desk of President

Dear Friends,

Greetings from BDMAI!

I am personally positive about the recent developments in the global trade environment and the evolving domestic policy landscape. The recently concluded UK-India Free Trade Agreement and the advancing U.S.-India trade framework are expected to enhance India's access to two of the world's largest pharmaceutical markets. For the bulk drug and API sector, these developments hold promise in terms of improved market access, reduced trade barriers, greater regulatory cooperation, and stronger supply chain integration.

At the same time, the Union Budget 2026-27 has provided targeted support aimed at strengthening domestic manufacturing, promoting innovation, encouraging R&D investments, and reinforcing India's position as a reliable global pharmaceutical hub. While we may need some time to fully assess the actual impact of these initiatives, the overall direction is encouraging for the bulk drug industry.

On the state front, BDMAI actively supported the Pharma Conclave organized by UPSIDA on 3rd February 2026 at Lucknow, held under the chairmanship of the Hon'ble Chief Minister of Uttar Pradesh. The Government of Uttar Pradesh is developing a Bulk Drug Park at Lalitpur, offering land at attractive rates along with several fiscal incentives.

This presents a significant opportunity for expansion and diversification. If a considerable number of our members express interest, BDMAI will take up the matter with the authorities to negotiate further on pricing and facilitation support.

BDMAI continues to proactively represent industry concerns with various Government departments and regulatory authorities. We are also organizing seminars and workshops on key industry-related subjects to enhance awareness and technical preparedness.

In this context, I request all members to participate in the important technical seminar on "Best Practices for Minimising Chloromethane Emissions and SOPs for Utilizing Hazardous Wastes" scheduled on 13th February 2026, at Hyderabad. The subject is relevant in the present regulatory and environmental compliance environment, and I encourage members to make the best use of this opportunity.

With best wishes,

Ch. A P Rameswara Rao
National President

In this Bulletin
you can expect

Global Pharma News

New Drug
Developments,
Investments & JVs
Drug Approvals,

BDMAI Activities

Representations
Circulars
Events

Technical / Commercial Articles

Data of Import & Export of Bulk Drugs

New Drug Developments

Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea

Nxera Pharma has reported encouraging top-line data from a phase 3 clinical trial of its insomnia treatment daridorexant in South Korea, paving the way for a planned marketing submission in early 2026. The study evaluated a 50 mg dose of daridorexant in both adult and elderly patients with insomnia. According to the company, the trial met all primary and secondary endpoints, showing significant improvements in subjective total sleep time, subjective latency to sleep onset and subjective wake after sleep onset when compared with placebo. The incidence of adverse events was similar across treatment and placebo groups.

Pharma Times 19.1.2026

Corxel raises \$287m as obesity continues to spark investor interest

Corxel's lead candidate, CX11, currently in a Phase II trial in the US and a Phase III trial in China, has raised \$287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug pipelines is showing no signs of slowing. China-headquartered Corxel secured the tranche in a Series D1 financing round, with SR One, TCGX, and RA Capital Management, among others, joining as new investors. Existing investors, RTW Investments and Hengdian Group Capital, also participated. Proceeds from the round

will support the development of the biopharma's lead candidate CX11, an oral glucagon-like peptide-1 receptor agonist (GLP-1RA). The pill is currently being evaluated in a Phase II trial in the US (NCT07011797) and a Phase III trial (NCT06939296) in China in obese and overweight patients.

Pharmaceutical Technologies 23.1.2026

Strong clinical data for Breye lead asset danegaptide

Breye Therapeutics has reported promising early clinical findings for its lead oral therapy danegaptide, following a presentation at the Angiogenesis, Exudation and Degeneration 2026 symposium. The data, presented by Prof. Carl Regillo, detailed results from a phase 1b study involving 24 patients with non-proliferative diabetic retinopathy (NPDR) and associated macular oedema. The multi-centre, open-label trial, conducted across 11 sites in the UK, Germany and the US, assessed safety, tolerability, pharmacokinetics and early biological activity. Danegaptide is described as a first-in-class oral small molecule designed to stabilise the vasculature and protect against retinal capillary breakdown and vascular leakage caused by hyperglycaemia.

Pharma Times 9.2.2026

AstraZeneca bladder cancer therapy wins NICE backing

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, marking the first time a perioperative immune-oncology treatment has been approved for cisplatin-eligible patients with muscle-invasive bladder cancer. The decision follows results from the Niagara phase 3 trial, which showed that durvalumab improved overall survival, with 82.2% of patients alive at 24 months compared with 75.2% in the comparison group. The study also demonstrated a 25% reduction in the risk of death and a 32% reduction in the risk of progression compared with standard neoadjuvant cisplatin-based chemotherapy.

Pharma Times 10.2.2026

Drug Approvals:

UK's MHRA gives high-dose Wegovy the go-ahead in obesity

In a landmark move for UK patients with obesity, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the maximum 7.2mg dose of Novo Nordisk's Wegovy (semaglutide) for chronic weight management purposes. Following its MHRA go-ahead, Wegovy will be available to adults with obesity and a body mass index (BMI) of 30kg/m² or higher at a dose of 7.2mg, which should be administered as three consecutive 2.4mg doses. Wegovy's use is not permitted in patients whose BMI lies under this value,

or to those using the medication to lower their risk of cardiovascular disease

FDA Grants Breakthrough Status to Immix AL Amyloidosis Therapy

Immix Biopharma, Inc., a clinical-stage biotechnology company focused on developing therapies for difficult-to-treat diseases, has received a major regulatory boost after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its lead candidate, NXC-201, for the treatment of relapsed or refractory AL amyloidosis. The designation underscores the urgent need for effective therapies in a disease area where no approved treatments currently exist for patients who relapse or fail standard care

Pharma Journalist 30.1.2026

Investments / JVs

Synaffix and Sidewinder Partner to Develop Next-Generation Bispecific ADCs

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The collaboration brings together complementary technologies designed to improve the precision, safety, and effectiveness of ADC-based cancer treatments.

Pharma Journalist 9.1.2026

Sun Pharma's Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

Sun Pharma, a speciality generics company with focuses in innovative treatments and consumer healthcare, has announced that Unloxcyt (cosibelimab) is now available in the US for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who cannot receive either curative surgery or curative radiation. Unloxcyt was recently approved for an updated label from the US Food and Drug Administration (FDA): the label has been updated following results from the CK-301-101 clinical trial in patients with mCSCC and laCSCC. Unloxcyt showed durable responses in these patient groups. Overall, 50% of patients demonstrated either complete or partial response to treatment, with 13% of mCSCC patients and 26% of laCSCC patients achieving complete response.

Pharma Times 21.1.2026

Santhera Licenses AGAMREE to Nxera in Key Asia-Pacific Markets

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK to develop, manufacture, and commercialize AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia, and New Zealand. The deal marks a major step in Santhera's strategy to expand global access to its flagship therapy while leveraging Nxera's

established presence and expertise across the Asia-Pacific region.

Pharma Journalist 9.1.2026

Novartis Licenses SciNeuro's Brain-Targeting Alzheimer's Antibody Program

SciNeuro Pharmaceuticals has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG to advance a novel antibody program for the treatment of Alzheimer's disease. The agreement grants Novartis exclusive global rights to develop and commercialize SciNeuro's amyloid beta-targeted antibody candidates, which are designed to improve drug delivery to the brain using SciNeuro's proprietary blood-brain barrier shuttle technology

Pharma Journalist 14.1.2026

ErVimmune raises 17m euros in funding to develop cancer vaccine

ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has announced a total of 17m euros in new funding, allowing it to advance its cancer vaccine candidate. The company's lead candidate, ErVac01, is a heterologous vaccine formulation containing a collection of human endogenous retrovirus (HERV)-derived epitopes, designed to cover the majority of the worldwide population in terms of HLA alleles. The selection of antigens shared across multiple patients and tumours means that the vaccine could be created as a ready-to-use product, rather than needing to be personalised for each individual patient.

Pharma Times 24.1.2026

Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases. Agreed in December 2025, the [transaction](#) is valued at up to \$820m and brings the late-stage monoclonal antibody brelovitug, a candidate for chronic hepatitis delta virus (HDV), into Mirum's global portfolio. With this deal closure, Mirum secures worldwide rights to the fully human antibody, currently in trials for HDV, a condition lacking approved therapies in the US.

Pharmaceutical Technologies 27.1.2026

WuXi Biologics, Sinorda Partner on Bispecific Antibody for IBD

WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and manufacturing of SND006, a novel bispecific antibody being developed for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune disorders. The partnership brings together Sinorda's proprietary biologics innovation with WuXi Biologics' global-scale contract research, development, and manufacturing capabilities, aiming to accelerate SND006 toward clinical development

Pharma Journalist 30.1.2026

Eli Lilly bets on in vivo cell therapy in \$2.4bn Orna Therapeutics buyout

Eli Lilly is acquiring *in vivo* cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to \$2.4bn. Through the agreement, Lilly will gain access to Orna's new class of circular RNA (circRNA) and lipid nanoparticle-based therapies, which are designed to trigger the creation of therapeutic proteins by a recipient's immune system to treat autoimmune diseases *in vivo*. ORN-252 lies at the heart of this deal, which Orna is developing to treat B-cell-driven autoimmune diseases. The *in vivo* CAR-T therapy targets the CD19 lymphocyte surface antigen and is set to enter clinical trials.

Pharmaceutical Technologies 9.2.2026

Eisai signs \$388m deal for Japanese rights to Henlius' anti-PD-1 mAb

Japanese pharmaceutical giant Eisai has forged an oncology licensing deal worth up to \$388m with Shanghai Henlius Biotech. Through this deal, Eisai will pay \$75m up front for the rights to develop and commercialise Henlius' marketed anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) Hetronify (serplulimab) in Japan, which has already gained approval across several solid tumour indications within China. Henlius will also be eligible to receive regulatory and sales milestone payments of up to \$80m and \$233m, respectively, as well as double-digit royalties on any sales made within the country.

Pharmaceutical Technology 5.2.2026

Calla Lily Clinical Care and Merck announce collab to advance drug delivery platform

Callavid is a transformational leak-resistant medical device designed to address challenges associated with the self-administration of vaginal therapeutics. Administration via the vaginal route can be associated with increased patient anxiety related to positioning, dosing accuracy, and concerns around leakage, particularly for certain therapeutics used in fertility treatments, oncology, and hormone therapies. Thang Vo-Ta, co-founder and CEO of Calla Lily Clinical Care, said:

“This collaboration with Merck marks an important milestone in the development of Callavid, our novel vaginal drug delivery platform. Merck’s scientific heritage and forward-looking approach to innovation make them an ideal partner as we work to address long-standing unmet needs in women’s health. By improving how vaginal therapeutics are delivered and experienced, Callavid has the potential to enhance both patient outcomes and quality of life. We see this collaboration as a meaningful step toward translating our technology into real-world clinical and patient impact.”

Pharmaceutical Manufacturer 10.2.2026

ASSOCIATION ACTIVITIES

Events:

BDMAI actively supported the Pharma Conclave organized by Uttar Pradesh State Industries Development Authority (UPSIDA) on 3rd February 2026 at Lucknow under the chairmanship of Hon'ble Chief Minister of Uttar Pradesh.



ASSOCIATION ACTIVITIES

Circulars

BDMAI sent the following circulars to the members about various events / updates:

Sl No.	Subject	Date and Link
01	Conference on Air Quality Management in Hyderabad organised by Planning department, TG & TSPCB	21.01.2026
02	Solid Waste Management Rules – Notification No. S.O. 388 (E) by MoEF dt. 27.1.2026 – Proposal by Hyderabad Integrated MSW Ltd for collection of Industrial MSW Wastes.	02.02.2026
03	Seminar on Best Practices to minimize Chloromethane Emissions & SOPs to utilize Hazardous Wastes in Bulk Drug Industry	05.02.2026
04	Scheme for promotion of Domestic Production of Fermentation based Bulk Drugs-Inputs required for DoP	06.02.2026

Representations:

Scheduling of Drugs / Chemicals under NDPS Act

BDMAI received a communication from Department of Pharmaceuticals indicating that they are proposing to include certain drugs/chemicals under NDPS Act and seeking industry inputs. Based on inputs received from the stakeholders, we submitted a detailed representation to the Department of Pharmaceuticals. Please click [HERE](#) to see the representation.

e-BRCs for Deemed exports:

It is understood some of the members that submission of e-BRCs for deemed exports, where proceeds will be realized in INR, which is technically not possible. Based on the request from members, we made a representation to DGFT. Please click [HERE](#) to see the representation.

EXPORTS OF BULK DRUGS

Values in Rs. Crore

S.No.	HSCode	Commodity	Apr-Nov2024	Apr-Nov2025	%Growth
1	17023010	GLUCOSE LIQUID	300.36	310.27	3.30
2	17023020	GLUCOSE SOLID	65.37	39.08	-40.22
3	17023031	DEXTROSE,SOLID	91.53	94.01	2.70
4	17023039	DEXTROSE OTHER THAN SOLID	1.86	1.87	0.90
5	17024039	DEXTROSE OTHER THAN SOLID	0.66	0.43	-35.68
6	29051410	ETHAMBUTOL, ETHAMBUTOL HCL	42.32	27.25	-35.60
7	29051420	SALBUTAMOL SULPHATE	68.88	63.41	-7.95
8	29054300	MANNITOL	31.49	40.68	29.22
9	29054400	D-GLUCITOL (SORBITOL)	352.59	379.17	7.54
10	29071930	THYMOL	48.39	39.00	-19.40
11	29072200	HYDROQUINONE (QUINOL) AND ITS SALTS	56.63	69.13	22.09
12	29095010	GUAIACOL	9.89	13.91	40.65
13	29124920	HELIOTROPINE (PIPERONYL ALDEHYDE)	0.01	0.00	-99.99
14	29124940	3,4,5-TRIMETHOXY-BENZALDEHYEDE	12.93	12.84	-0.66
15	29154010	MONOCHLOROACETIC ACID,THR SALTS AND ESTERS	79.92	67.09	-16.06
16	29163120	BENZYL BENZOATE	31.38	20.15	-35.77
17	29163150	BENZOCAINE (ETHYL PARA-AMINO BENZOATE)	10.74	19.88	85.03
18	29163400	PHENYLACETIC ACID AND ITS SALTS	6.54	6.22	-4.89
19	29171940	FERROUS FUMERATE	47.62	42.41	-10.94
20	29171970	ETHOXY METHYLENE MALONATE,DIETHYL MALONATE	0.04	1.40	3,271.23
21	29181120	CALCIUM LACTATE	1.40	0.86	-38.60
22	29181320	METOPROLOL TARTRATE	52.06	55.82	7.22
23	29181510	POTASSIUM CITRATE	16.94	14.37	-15.15
24	29181520	SODIUM CITRATE	58.51	62.87	7.46
25	29181550	FERRIC AMMONIUM CITRATE	3.80	6.92	82.04
26	29181610	CALCIUM GLUCONATE	42.84	29.49	-31.18
27	29181620	FERROUS GLUCONATE	6.44	3.78	-41.35
28	29182110	SALICYLIC ACID	15.77	20.80	31.91
29	29182120	SODIUM SALICYLATE	15.30	13.49	-11.82
30	29182200	O-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS	7.77	8.74	12.46
31	29182310	METHYL SALICYLATE	42.23	46.56	10.26
32	29182320	AMINO SALICYLATE	3.02	3.57	18.36
33	29183030	NALIDIXIC ACID	10.03	5.39	-46.26
34	29199010	GLYCEROPHOSPHATE ACID	0.15	0.37	140.43
35	29199030	IRON GLYCEROPHOSPHATE	0.34	0.12	-66.30
36	29214236	METHYL DOPA(L-ALPHA METHYL-3, 4-DIHYDROXYPHENYLALANINE)	0.87	1.57	80.69

37	29214600	AMFETAMINE BENZFETAMINE ETC THR SALTS	164.87	376.61	128.44
38	29215110	O- PHENYLENEDIAMINE	5.10	6.17	21.04
39	29215120	M-PHENYLENEDIAMINE (M- DIAMINOBENZENE)	50.63	150.65	197.53
40	29215130	P-PHENYLENEDIAMINE	60.93	42.97	-29.47
41	29215170	PARA-AMINO ACETANILIDE	1.43	2.88	101.96
42	29223100	AMFEPRA NONE(INN), METHDONE AND MORMETHADONESALTS	2.75	5.47	98.97
43	29224100	LYSINE AND ITS ESTERS SALTS THEREOF	12.62	21.78	72.58
44	29224210	GLUTAMIC ACID	1.26	1.55	22.93
45	29224220	MONOSODIUM GLUTAMATE (AZINAMOTO)	3.74	3.31	-11.64
46	29224400	TILIDINE (INN) AND ITS SALTS	1.96	0.33	-83.30
47	29224910	AMINO ACETIC ACID (GLYCINE)	132.65	91.23	-31.23
48	29224920	N-METHYL TAURINE	0.16	0.29	81.00
49	29225011	PARA-AMINO-SALICYLIC ACID	0.01	0.07	474.01
50	29225013	PROCAINE HYDROCHLORIDE	0.43	0.81	86.09
51	29225015	L-TYROSINE(P- HYDROXYPHENYLAMINE)	0.08	0.04	-50.37
52	29225021	FRUSEMIDE	104.80	100.53	-4.07
53	29225024	DOMPERIDONE	44.37	38.39	-13.47
54	29231000	CHOLINE AND ITS SALTS	62.48	46.15	-26.13
55	29241100	MEPROBAMATE (INN)	21.86	3.04	-86.09
56	29242910	ACETANILIDE	1.79	0.72	-60.01
57	29242960	PYRAZINAMIDE(PYRAZINE CARBOXAMIDE)	33.62	18.66	-44.49
58	29242970	Pretilachlor (ISO)	0.31	95.09	30,485.28
59	29262000	1- CYANOQUANIDINE(DICYANDIAMIDE)	0.01	0.88	6,089.98
60	29263000	FENPROPOREX (INN) AND ITS SALTS	0.31	0.00	-99.39
61	29264000	ALPHA-PHENYLACETOACETONITRILE		0.12	
62	29280010	ISONIAZID	6.04	5.73	-5.09
63	29304000	METHIONINE	2.13	2.95	38.37
64	29309040	L-CYSTINE (ALPHA-AMINO BETA- THIO PROPIONICACID)- SULPHUR CONTAINING AMINO ACID	17.70		
65	29322010	COUMARIN, METHYLCOUMARINS AND ETHYLCOUMARINS	54.94	62.36	13.50
66	29329300	PIPERANOL	1.55	0.00	-100.00
67	29329600	CARBOFURAN (ISO)	0.06	3.02	5,113.33
68	29331100	PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES	54.14	55.72	2.91

69	29331910	3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE	9.91	12.80	29.21
70	29331920	1(2:5 DCHLR-4-SLPHPHNYL)-3- MTHYL-5-PYRAZLN	4.69	57.58	1,128.08
71	29331930	3-MTHYL-1(4-SLPHO-0-TOLUYL-5- PYRAZOLDNE)	5.89	0.73	-87.66
72	29331940	PHENYL-METHYL PYRAZOLONE	0.19	0.22	17.00
73	29331950	1-PHNYL-5-PYRAZLN-3-CRBOXYLC ACD ETHYLESTR	0.16	0.02	-86.93
74	29331960	1-(M-SULPHOPHENYL)-3- PYRAZOLONE		0.51	
75	29331970	ANALGIN	0.62		
76	29332910	TINIDAZOLE	19.02	23.24	22.18
77	29332920	METRONIDAZOLE METRONIDIAZOLE BENZOATE	80.83	99.70	23.35
78	29332930	MEBENDAZOLE	29.46	43.47	47.58
79	29332940	DIMETRIDAZOLE	43.10	22.97	-46.71
80	29332950	ALBENDAZOLE	70.64	100.93	42.89
81	29332960	Imidacloprid (ISO)	0.00	28.17	100.00
82	29333914	CHLORPHENIRAMINE MALEATE	31.90	30.58	-4.14
83	29333917	Chlorantraniliprole (ISO)	0.43	0.63	46.44
84	29333921	Acetamidprid (ISO)	0.69	0.00	-99.48
85	29333922	Imazethapyr (ISO)	20.49	27.23	32.92
86	29333929	Other	901.23	856.68	-4.94
87	29334100	LEVORPHANOL (INN) AND ITS SALTS	11.32		
88	29335200	MALONYLUREA (BARBITURIC ACID) AND ITS SALS	2.67	6.92	159.44
89	29335300	ALLOBARBITAL AND OTHR BARBITAL COMPND S ANDITS SALTS	25.35	15.05	-40.63
90	29335400	OTHER DERIVATIVES OF MALONYLUREA (BARBITURIC ACID), SALTS THEREOF	8.60	9.71	12.94
91	29335910	AMINOPHYLLINE(CORDOPHYLIN)	3.95	3.66	-7.44
92	29335920	TRIMETHOPRIM	70.02	74.38	6.22
93	29335930	DIETHYL CARBANAZINE CITRATE	5.54	1.68	-69.72
94	29335940	1 - AMINO-4METHYL PIPERAZINE	16.22	43.60	168.85
95	29335950	Bispyribac-sodium (ISO)	5.82	56.28	867.28
96	29339100	ALPRA ZOLAM, CAMAZEPAM AND OTHER CMPNDS OF ZEPAM, SALTS THEREOF	115.65	115.56	-0.08
97	29339200	AZINPHOS-METHYL (ISO)	0.88	1.79	102.22
98	29339920	Carbendazim (ISO)	0.14	42.94	29,692.75
99	29349100	AMINOREX, BROTILOLAM AND OTHER LIKE CMPNDS, SALTS THEREOF	37.53	79.41	111.61
100	29349200	OTHER FENTANYLS AND THEIT DERIVATIVES	0.51	4.63	800.51

101	29349910	CHIARO THIOPHENE-2-CARBOXYLIC ACID	0.37	0.32	-11.87
102	29349920	MORPHOLINE	84.71	81.32	-4.01
103	29349990	OTHER	3,201.10	3,953.85	23.52
104	29351000	N-METHYLPERFLUOROCTANE SULPHONAMIDE	0.38	2.29	506.94
105	29355010	Flubendiamide (ISO)	0.03		
106	29355090	Other	9.94	9.57	-3.77
107	29359011	SULPHAMETHOXAZOLE	191.23	164.74	-13.85
108	29359012	SULPHAFURAZOLE	0.05	0.01	-69.94
109	29359013	SULPHADIAZINE	30.71	38.35	24.91
110	29359014	SULPHADIMIDINE	0.45	0.16	-65.22
111	29359015	SULPHACETAMIDE	0.05	0.21	299.02
112	29359022	SULPHAMETHIAZOLE		25.90	
113	29362100	VITAMINS A AND THEIR DERIVATIVES	127.79	118.34	-7.40
114	29362210	VITAMIN B1(THIAMINE, ANEURINE) AND ITS SALT	60.82	62.60	2.93
115	29362290	OTHER VITAMIN B1 AND ITS DERIVATIVES	119.66	79.83	-33.29
116	29362310	VITAMIN B2 (RIBOFLAVIN, LACTOPLAVIN) AND ITS SALTS	60.51	72.84	20.38
117	29362390	OTHER VITAMIN B2 AND ITS DERIVATIVES	1.17	0.83	-29.57
118	29362400	D-OR DL-PANTOTHENIC ACID (VITAMIN B5) AND ITS DERIVATIVES	4.37	2.21	-49.59
119	29362500	VITAMIN B6 AND ITS DRVTS	1.20	5.09	324.44
120	29362610	VITAMIN B12 (CYNOCOBALAMIN)	3.81	9.03	137.23
121	29362690	OTHER VITAMIN B12 AND ITS DERIVATIVES	23.14	61.29	164.91
122	29362700	VITAMIN C (ASCORBIC ACID) AND ITS DRVTVS	58.07	71.62	23.33
123	29362800	VITAMIN E AND ITS DERIVATIVES	107.56	144.98	34.79
124	29362910	FOLIC ACID (VITAMIN B9)	30.82	36.28	17.73
125	29362920	NCTNC ACID AND NCTNMD(NIACINAMIDE/NIACINE	510.47	457.22	-10.43
126	29362930	VITAMIN K (MENAPHTHONUM B.P.)	39.35	52.71	33.93
127	29362940	VITAMIN D	124.27	170.88	37.51
128	29362950	VITAMIN H (BIOLIN)	4.70	3.14	-33.31
129	29362990	OTHER VITAMINS AND THR DRVTVS	104.88	109.19	4.11
130	29369000	OTHER, INCL. NATURAL CONCENTRTS	232.21	327.87	41.19
131	29371100	SOMATOTROPIN, ITS DRVTVSAND STRCTL ANALOGVES	1.76	0.57	-67.32
132	29371200	INSULIN AND ITS SALTS	231.98	230.44	-0.67

133	29371900	OTHER POLYPEPTIDE HORMONES THR DTVTVS AND STRCTL ANLGES	181.67	237.32	30.63
134	29372100	CORTISONE, HYDROCORTISONE, PRED NISONE (DEHY-DROCORTISONE) AND FREDNISOLONE AND PRDNSLN (DEHYDROHYDROCORTISON E)	68.69	74.14	7.94
135	29372200	HALGNTD DRVTVS OF CORTI COSTEROIDAL	193.79	189.44	-2.24
136	29372300	OESTROGENS AND PROGESTOGENS	133.54	150.79	12.92
137	29372900	OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES	625.72	650.78	4.00
138	29375000	PROSTAGLANDINS, TIROMBOXAMES AND LEUKOTRIENESTHR DRVTVS AND STRCLT ANLGES	12.12	8.99	-25.82
139	29379011	EPINETHRINE	0.06		
140	29379019	OTHER	6.81	3.69	-45.90
141	29379020	AMINO-ACID DERIVATIVES	124.25	77.40	-37.71
142	29379090	OTHER	158.71	124.47	-21.58
143	29381000	RUTOSIDE (RUTIN) AND ITS DERIVATIVES	0.01	0.01	-26.49
144	29389010	DIGOXIN	11.28	8.92	-20.94
145	29389090	OTHER GLYCOSIDES NTRL/RPRDCD BY SYNTHESIS AND THR SLTS ETHRS DRVTVS	233.60	451.85	93.43
146	29391100	CONCENTRATES OF POPPY STRAW CMPNDS OF MORPHIN, CODEINE, CODONE, THE BAINE, SALTS THEREOF	7.93	1.13	-85.81
147	29392010	QUININE ALKALOIDS	0.00	0.00	3.72
148	29392020	QUININE HYDROCHLORIDE	12.21	24.91	104.06
149	29392030	QUININE SULPHATE	6.55	2.98	-54.57
150	29392040	CHLOROQUINE PHOSPHATE	9.22	9.58	3.93
151	29393000	CAFFEINE AND ITS SALTS	320.12	400.36	25.07
152	29394100	EPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	11.63	13.16	13.12
153	29394400	NOREPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	11.70	19.89	70.06

154	29394500	LEVOMETAMFETAMINE,METAMFETA MINE (INN),METAMFETAMINERACEMATE,T HR SALTS (ALKALOIDS OF EPHEDRA,THR DRVTVS; SALTS THEIR OF)	0.63	0.00	-99.87
155	29394900	OTHER	13.83	10.42	-24.62
156	29395900	OTHER THEOPHYLLINE AND AMINOPHYLLINE THR DRVTVS, SALTS	199.92	264.61	32.35
157	29396900	OTHER, OF VEGETAL ORIGIN	13.03	10.03	-23.05
158	29397900	OTHER	670.98	934.65	39.30
159	29398000	OTHER	89.13	83.40	-6.43
160	29411010	PENICILLINS AND ITS SALTS	0.13	1.22	851.34
161	29411020	AMPICILLINE AND ITS SALTS	149.34	133.33	-10.72
162	29411030	AMOXYCILLINE AND ITS SALTS	1,042.65	870.94	-16.47
163	29411040	CLOXACILLINE AND ITS SALTS	132.72	124.00	-6.57
164	29411050	6 - APA	0.00	0.00	7,275.81
165	29411090	OTHER PENICILLINS AND THR DRVTVS WTH A PENTCILLIANIC ACID STRCTR SLTS THEREOF	502.86	439.51	-12.60
166	29412010	STREPTOMYCINS	0.06	0.28	365.31
167	29412090	OTHER STREPTOMYCINE AND DRVTVS, SALTS	0.18	2.52	1,309.18
168	29413010	DOXYCYLIME AND ITS SALTS	3.57	5.03	40.73
169	29413020	TETRACYCLINE/OXYTETRA - CYCLINE AND HR SALTS	12.70	6.19	-51.24
170	29413090	OTHER TETRACYCLINES AND THR DRVTVS SLTS	2.51	1.99	-20.55
171	29414000	CHLORAMPHENICOL AND ITS DRVTVS SLTS THEREOF	13.37	12.78	-4.38
172	29415000	ERTHROMYCIN AND ITS DRVTVS SLTS THEREOF	569.53	540.77	-5.05
173	29419011	RIFAMPICIN	55.30	79.39	43.55
174	29419013	RIFA OR RIFA S SODIUM (RIFAINT)	1.69		
175	29419019	OTHER RIFAMPICIN AND ITS SALTS	49.59	26.88	-45.79
176	29419020	CEPHALEXIN AND ITS SALTS	59.27	37.10	-37.40
177	29419030	CIPROFLOXACINE AND ITS SALTS	117.53	131.53	11.91
178	29419040	GENTAMYCIN AND ITS SALTS	0.27	0.11	-61.24
179	29419050	NEOMYCIN	0.15	0.60	303.13
180	29419060	NORFLOXACIN AND ITS SALTS	9.89	12.36	25.02
181	29419090	OTHER ANTIBIOTICS	3,098.93	2,685.61	-13.34
182	29420011	CEFADROXIL	104.99	108.18	3.04
183	29420012	IBUPROFANE	409.10	392.77	-3.99
184	29420013	NIFEDIPINE	9.06	17.37	91.77
185	29420014	RANITIDINE	57.08	45.52	-20.25

186	29420015	DANES SALT OF D (-) PHENYL GLYCINE	1.29		
187	29420016	D(-) PARA HYDROXY DANES SALTS	0.03	0.19	450.44
188	29420021	TIMOLOL MALEATE	28.00	24.62	-12.06
189	29420022	TERBUTOLINE SULPHATE	7.14	6.98	-2.25
190	29420024	IMIPRAMINE HCL	3.68	5.34	45.18
191	29420025	AMITRYPTYLINE HCL	33.59	32.85	-2.22
192	29420026	CYSTEANUNE HCL	0.00	0.00	-94.91
193	29420027	ATENOLOL, PROPRONALOL	60.68	67.93	11.95
194	29420031	DILOXANIDE FUROATE	12.27	19.19	56.35
195	29420032	CIMETIDINE	0.01	0.31	4,468.42
196	29420033	OXYCLOZANIDE	33.44	52.58	57.26
197	29420034	FAMOTIDINE	70.31	79.83	13.54
198	29420090	OTHER DILOXANIDE FUROATE, CIMETIDINE, FAMOTIDINE NES	5,829.48	6,088.87	4.45
199	30034100	CONTAINING EPHEDRINE OR ITS SALTS	7.47	15.13	102.65
200	30034900	OTHER	4.23	1.04	-75.44
201	30036000	OTHER, CONTAINING ANTIMALARIAL ACTIVE PRINCIPLES DESCRIBED IN SUB HEADING NOTE 2 OF CHAPTER 30	2.18	0.61	-72.12
202	30044100	CONTAINING EPHEDRINE OR ITS SALTS	4.64	3.16	-32.00
203	30044200	CONTAINING PSEUDOEPHEDRINE (INN) OR ITS SALTS	0.01	1.06	9,344.19
204	30044300	CONTAINING NOREPHEDRINE OR ITS SALTS	0.13	1.02	658.14
205	30044910	ATROPIN AND SALTS THEREOF	21.38	12.87	-39.79
206	30044920	CAFFEIN AND SALTS THEREOF	24.73	14.29	-42.21
207	30044930	CODEINE AND DERIVATIVES, WITH OR WITHOUT EPHEDRINE HYDROCHLORIDE	31.04	43.35	39.64
208	30044940	ERGOT PREPARATIONS, ERGOTAMINE AND SALTS THEREOF	0.50	1.33	167.93
209	30044950	PAPAVARINE HYDROCHLORIDE	1.86	2.06	10.83
210	30044960	BROMOHEXIN AND SOLBUTAMOL	11.04	12.61	14.20
211	30044970	THEOPHYLLINE AND SALTS THEREOF	0.18	1.55	770.03
212	30044990	OTHER	49.67	70.13	41.19
213	96020030	GELATIN CAPSULES,EMPTY	482.45	463.41	-3.95
		India's Total Export of BULK DRUGS	25513.48	27166.74	6.48

BULK DRUGS IMPORTS

Values in Rs					
S.No.	HSCode	Commodity	Apr-Nov2024	Apr-Nov2025	%Growth
1	17023010	GLUCOSE LIQUID	0.35	0.79	128.33
2	17023020	GLUCOSE SOLID	4.32	4.19	-2.93
3	17023031	DEXTROSE,SOLID	4.23	3.44	-18.67
4	17023039	DEXTROSE OTHER THAN SOLID	5.42	7.61	40.54
5	17024031	DEXTROSE SOLID			
6	17024039	DEXTROSE OTHER THAN SOLID	0.95	1.13	19.54
		ETHAMBUTOL, ETHAMBUTOL			
7	29051410	HCL	21.81	18.30	-16.13
8	29051420	SALBUTAMOL SULPHATE	1.72	2.42	41.01
9	29054300	MANNITOL	292.11	327.88	12.25
10	29054400	D-GLUCITOL (SORBITOL)	61.18	62.25	1.74
12	29071930	THYMOL	0.51	0.64	24.49
		HYDROQUINONE (QUINOL) AND			
13	29072200	ITS SALTS	189.95	196.13	3.25
14	29095010	GUAIACOL	7.90	17.81	125.38
16	29124930	THIACETAZONE	0.10		
		3,4,5-TRIMETHOXY-			
17	29124940	BENZALDEHYEDE	2.26	2.51	10.74
		MONOCHLOROACETIC ACID,THR			
18	29154010	SALTS AND ESTERS	15.62	10.12	-35.25
19	29163120	BENZYL BENZOATE	2.97	6.06	104.26
		BENZOCAINE (ETHYL PARA-			
20	29163150	AMINO BENZOATE)	0.16	0.73	363.34
		PHENYLACETIC ACID AND ITS			
21	29163400	SALTS	35.74	13.22	-63.02
22	29171940	FERROUS FUMERATE	0.23	0.41	74.45
		ETHOXY METHYLENE			
23	29171970	MALONATE,DIETHYL MALONATE	111.46	85.48	-23.31
24	29181120	CALCIUM LACTATE	2.34	1.60	-31.58
25	29181320	METOPROLOL TARTRATE	4.59	11.49	150.03
26	29181510	POTASSIUM CITRATE	10.52	5.40	-48.67
27	29181520	SODIUM CITRATE	12.95	25.07	93.59
28	29181550	FERRIC AMMONIUM CITRATE	0.04	0.12	194.30
29	29181610	CALCIUM GLUCONATE	49.92	45.02	-9.83
30	29181620	FERROUS GLUCONATE		0.20	
31	29182110	SALICYLIC ACID	160.79	122.52	-23.80
32	29182120	SODIUM SALICYLATE	0.33	0.97	194.98
		O-ACETYSALICYLIC ACID ITS			
33	29182200	SALTS AND ESTRS	3.57	3.23	-9.53
34	29182310	METHYL SALICYLATE	6.25	4.99	-20.07
35	29182320	AMINO SALICYLATE		0.30	
36	29183030	NALIDIXIC ACID	4.67	2.76	-40.86
37	29199010	GLYCEROPHOSPHATE ACID	0.02	0.36	1,790.83
38	29199030	IRON GLYCEROPHOSPHATE			
		METHYL DOPA(L-ALPHA			
		METHYL-3, 4-			
39	29214236	DIHYDROXYPHENYLALANINE)	79.07	77.84	-1.55
		AMFETAMINE BENZFETAMINE			
40	29214600	ETC THR SALTS	2.52	1.86	-26.19

41	29215110	O- PHENYLENEDIAMINE	95.94	68.69	-28.41
42	29215120	M-PHENYLENEDIAMINE (M-DIAMINO BENZENE)	22.06	20.92	-5.18
43	29215130	P-PHENYLENEDIAMINE	27.23	23.60	-13.32
47	29223100	AMFEPRA NONE(INN), METHDNE AND MORMETHADONESALTS		0.01	
48	29224100	LYSINE AND ITS ESTERS SALTS THEREOF	673.53	655.98	-2.61
49	29224210	GLUTAMIC ACID	4.32	4.70	8.77
50	29224220	MONOSODIUM GLUTAMATE (AZINAMOTO)	344.03	359.66	4.55
51	29224400	TILIDINE (INN) AND ITS SALTS		0.00	
52	29224910	AMINO ACETIC ACID (GLYCINE)	151.45	105.17	-30.56
53	29224920	N-METHYL TAURINE	6.40	21.90	242.19
54	29225011	PARA-AMINO-SALICYLIC ACID	1.00	0.11	-89.40
55	29225013	PROCAINE HYDROCHLORIDE		0.12	
56	29225015	L-TYROSINE(P-HYDROXYPHENYLAMINE)	12.97	18.92	45.87
57	29225021	FRUSEMIDE	3.05	2.12	-30.69
59	29231000	CHOLINE AND ITS SALTS	16.24	13.96	-14.03
60	29241100	MEPROBAMATE (INN)	15.18	7.04	-53.61
62	29242500	ALACHLOR (ISO)		0.03	
63	29242910	ACETANILIDE	81.43	73.44	-9.81
64	29242960	PYRAZINAMIDE(PYRAZINE CARBOXAMIDE)	7.96	5.67	-28.84
65	29242970	Pretilachlor (ISO)	14.16	19.55	38.03
67	29262000	1-CYANO GUANIDINE(DICYANDIAMIDE)	431.67	332.88	-22.89
68	29263000	FENPROPOREX (INN) AND ITS SALTS		8.06	
69	29264000	ALPHA-PHENYLACETOACETONITRILE	0.57	1.73	200.43
70	29280010	ISONIAZID	14.40	23.37	62.35
71	29304000	METHIONINE	966.00	967.69	0.17
72	29309040	L-CYSTINE (ALPHA-AMINO BETA-THIO PROPIONICACID)-SULPHUR CONTAINING AMINO ACID	99.70		
73	29322010	COUMARIN, METHYLCOUMARINS AND ETHYLCOUMARINS	6.33	4.98	-21.31
75	29329300	PIPERANOL	18.26	8.16	-55.30
78	29329600	CARBOFURAN (ISO)		22.01	
79	29331100	PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES	7.43	8.70	17.13
80	29331910	3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE	1.18	5.06	328.99
81	29331920	1(2:5 DCHLR-4-SLPHPHNYL)-3-MTHYL-5-PYRAZLN	0.61	2.87	369.73
82	29331930	3-MTHYL-1(4-SLPHO-0-TOLUYL)-5-PYRAZOLDNE)	0.02	0.02	-20.90
83	29331940	PHENYL-METHYL PYRAZOLONE	5.53	4.29	-22.52

84	29331950	1-PHNYL-5-PYRAZLN-3-CRBOXYLC ACD ETHYLESTR	0.00	2.50	83,675.38
85	29331960	1-(M-SULPHOPHENYL)-3-PYRAZOLONE	2.31	3.75	62.58
86	29331970	ANALGIN	22.48	12.74	-43.32
87	29331980	OXYPHENBUTAZONE	0.11	1.32	1,084.79
88	29332910	TINIDAZOLE	0.38	2.18	467.82
89	29332920	METRONIDAZOLE			
		METRONIDIAZOLE BENZOATE	66.29	57.43	-13.36
90	29332930	MEBENDAZOLE	0.99	0.45	-54.50
91	29332940	DIMETRIDAZOLE	0.98		
92	29332950	ALBENDAZOLE	8.14	12.83	57.62
93	29332960	Imidacloprid (ISO)		1.37	
94	29333914	CHLORPHENIRAMINE MALEATE	1.05	0.08	-92.39
95	29333917	Chlorantranilprole (ISO)		2.04	
96	29333921	Acetamiprid (ISO)		5.29	
98	29333929	Other	115.75	121.89	5.31
100	29335200	MALONYLUREA (BARBITURIC ACID) AND ITS SALS	27.10	35.12	29.59
101	29335300	ALLOBARBITAL AND OTHR BARBITAL COMPNDS ANDITS SALS	1.60	0.32	-79.84
102	29335400	OTHER DERIVATIVES OF MALONYLUREA (BARBITURIC ACID), SALS THEREOF	0.06	7.12	11,641.68
103	29335500	LOPRAZOLAM, MECLOQUALONE, METHAQUALONE , ZIPEROL, SALS THEREOF	0.01	0.00	-38.13
104	29335910	AMINOPHYLLINE(CORDOPHYLIN)	3.11	1.24	-60.25
105	29335920	TRIMETHOPRIM	1.91	2.30	20.27
107	29335940	1 - AMINO-4METHYL PIPERAZINE	0.10	0.16	58.63
108	29335950	Bispyribac-sodium (ISO)	0.00	0.09	5,788.86
109	29339100	ALPRA ZOLAM, CAMAZEPAM AND OTHER CMPNDS OF ZEPAM, SALS THEREOF	14.09	11.06	-21.56
110	29339200	AZINPHOS-METHYL (ISO)	0.00	0.00	275.70
111	29339920	Carbendazim (ISO)	0.02	10.07	43,340.35
112	29349100	AMINOREX, BROTILOLAM AND OTHER LIKE CMPNDS, SALS THEREOF	0.19	0.00	-98.13
113	29349200	OTHER FENTANYLS AND THEIT DERIVATIVES	4.42	2.85	-35.61
114	29349910	CHIARO THIOPHENE-2-CARBOXYL IC ACID	3.09	5.44	75.73
115	29349920	MORPHOLINE	32.74	31.89	-2.60
116	29349990	OTHER	3,791.38	3,872.05	2.13
117	29351000	N-METHYLPERFLUOROCTANE SULPHONAMIDE	0.19	0.00	-99.65
119	29353000	N-ETHYL-N-(2-HYDROXYETHYL) PERFLUOROCTANE SULPHONAMIDE	0.02	0.07	189.90

120	29355090	Other	0.48	8.37	1,660.29
121	29359011	SULPHAMETHOXAZOLE	0.22	0.35	61.51
123	29359013	SULPHADIAZINE	3.77	4.84	28.48
124	29359014	SULPHADIMIDINE	8.80	10.91	24.00
129	29359024	SULPHAMIDE	4.06	6.39	57.32
130	29362100	VITAMINS A AND THEIR DERIVATIVES	78.79	107.73	36.73
131	29362210	VITAMIN B1(THIAMINE, ANEURINE) AND ITS SALT	88.89	151.16	70.05
132	29362290	OTHER VITAMIN B1 AND ITS DRIVATIVES	18.00	15.63	-13.20
133	29362310	VITAMIN B2 (RIBOFLAVIN, LACTOPLAVIN) AND ITS SALTS	72.99	56.05	-23.21
134	29362390	OTHER VITAMIN B2 AND ITS DERIVATIVES	32.64	17.21	-47.28
135	29362400	D-OR DL-PANTOTHENIC ACID (VITAMIN B5) AND ITS DERIVATIVES	53.26	75.69	42.13
136	29362500	VITAMIN B6 AND ITS DRVTS	81.86	75.21	-8.13
137	29362610	VITAMIN B12 (CYNOCOBALAMIN)	152.95	186.72	22.08
138	29362690	OTHER VITAMIN B12 AND ITS DERIVATIVES	10.38	22.68	118.42
139	29362700	VITAMIN C (ASCORBIC ACID) AND ITS DRVTVS	120.84	190.50	57.65
140	29362800	VITAMIN E AND ITS DERIVATIVES	263.06	340.43	29.41
141	29362910	FOLIC ACID (VITAMIN B9)	15.11	39.18	159.36
142	29362920	NCTNC ACID AND NCTNMD(NIACINAMIDE/NIACIN E	9.77	7.23	-25.97
143	29362930	VITAMIN K (MENAPHTHONUM B.P.)	14.55	12.53	-13.88
144	29362940	VITAMIN D	76.99	100.60	30.66
145	29362950	VITAMIN H (BIOLIN)	8.98	10.26	14.30
146	29362990	OTHER VITAMINS AND THR DRVTVS	117.09	77.91	-33.46
147	29369000	OTHER, INCL. NATURAL CONCENTRTS	6.91	16.24	135.12
148	29371100	SOMATOTROPIN, ITS DRVTVSAND STRCTL ANALOGVES	0.06	0.02	-62.98
149	29371200	INSULIN AND ITS SALTS	164.17	301.00	83.35
150	29371900	OTHER POLYPEPTIDE HORMONES THR DTVTVS AND STRCTL ANLGES	225.19	386.76	71.75
151	29372100	CORTISONE, HYDROCORTISONE, P REDNISON (DEHY- DROCORTISONE) AND FREDNISOLONE AND PRDNSLN(DEHYDROHYDROCORT ISONE)	234.38	205.49	-12.32
152	29372200	HALGNTD DRVTVS OF CORTI COSTEROIDAL	157.49	153.88	-2.29
153	29372300	OESTROGENS AND PROGESTOGENS	346.03	324.46	-6.23

154	29372900	OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES	607.68	581.64	-4.28
155	29373100	EPINEPHRINE		0.01	
156	29375000	PROSTAGLANDINS, TIROMBOXAMESAND LEUKOTRIENESTHR DRVTVS AND STRCTL ANLGES	34.86	26.43	-24.17
157	29379011	EPINETHRINE	0.01	0.03	163.70
158	29379019	OTHER	28.82	26.25	-8.91
159	29379020	AMINO-ACID DERIVATIVES	67.65	43.17	-36.19
160	29379090	OTHER	329.35	353.89	7.45
161	29381000	RUTOSIDE (RUTIN) AND ITS DERIVATIVES	32.78	26.96	-17.76
162	29389010	DIGOXIN	0.22	0.99	343.52
163	29389020	DIGITALIS GLYCOSIDES	0.72	0.22	-69.83
164	29389090	OTHER GLYCOSIDES NTRL/RPRDCD BY SYNTHESIS ANDTHR SLTS ETHRS DRVTVS	405.21	358.27	-11.58
165	29391100	CONCENTRATES OF POPPY STRAW CMPNDS OF MORPHIN, CODEINE, CODONE, THE BAINE, SALTS THEREOF	148.89	18.51	-87.57
166	29392010	QUININE ALKALOIDS	4.04	5.95	47.41
167	29392020	QUININE HYDROCHLORIDE	0.03	2.60	7,980.91
168	29392030	QUININE SULPHATE	2.90	1.82	-37.19
170	29393000	CAFFEINE AND ITS SALTS	123.79	198.84	60.63
171	29394100	EPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.07	0.82	1,031.08
172	29394300	CATHINE (INN) AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.00	0.02	382.27
173	29394400	NOREPHEDRINE AND ITS SALTS (ALKALOIDS OF EPHEDRA AND THEIR DERIVATIVES; SALTS THEIR OF)	0.01	0.13	1,828.88
174	29394500	LEVOMETAMIFETAMINE,VIETAM FETAMINE (INN),METAMFETAMINERACEMA TE,THR SALTS (ALKALOIDS OF EPHEDRA,THR DRVTVS; SALTS THEIR OF)	0.01	0.01	-5.03
175	29394900	OTHER	3.26	4.56	39.66
176	29395900	OTHER THEOPHYLLINE AND AMINOPHYLLINE THR DRVTVS, SALTS	27.97	28.19	0.77
178	29396190	OTHER ERGOMETRINE SALTS	0.80	1.10	37.94
179	29396210	ERGOTAMINE TARTARATE	6.18		
180	29396290	OTHER ERGOTAMINE SALTS	0.30		
182	29396900	OTHER, OF VEGETAL ORIGIN	23.29	14.41	-38.13

183	29397200	COCAINE, ECGONINE; SALTS, ESTERS AND OTHER DERIVATIVES THEREOF	2.14	0.01	-99.75
184	29397900	OTHER	29.72	63.59	113.96
185	29398000	OTHER	57.14	24.60	-56.95
186	29411010	PENICILLINS AND ITS SALTS	1,293.97	736.17	-43.11
187	29411020	AMPICILLINE AND ITS SALTS	2.57	4.11	59.69
188	29411030	AMOXYCILLINE AND ITS SALTS	251.16	211.92	-15.62
189	29411040	CLOXACILLINE AND ITS SALTS	3.36	5.23	55.73
190	29411050	6 - APA	2,452.19	1,982.50	-19.15
191	29411090	OTHER PENICILLINS AND THR DRVTVS WTH A PENTCILLIANIC ACID STRCTR SLTS THEREOF	459.17	489.22	6.54
192	29412010	STREPTOMYCINS	33.28	30.80	-7.43
193	29412090	OTHER STREPTOMYCINE AND DRVTVS, SALTS	14.68	11.51	-21.60
194	29413010	DOXYCYLIME AND ITS SALTS	111.52	166.02	48.87
195	29413020	TETRACYCLINE/OXYTETRA - CYCLINE AND HR SALTS	57.38	68.07	18.64
196	29413090	OTHER TETRACYCLINES AND THR DRVTVS SLTS	126.95	126.83	-0.09
197	29414000	CHLORAMPHENICOL AND ITS DRVTVS SLTS THEREOF	14.92	2.32	-84.42
198	29415000	ERTHROMYCIN AND ITS DRVTVS SLTS THEREOF	926.56	1,092.62	17.92
199	29419011	RIFAMPICIN	202.05	349.86	73.15
201	29419013	RIFA OR RIFA S SODIUM (RIFAINT)	83.32	227.56	173.11
202	29419014	1 - AMINO -4 - METHYL PIPERAZINE (RIFAINT)	0.63		
203	29419019	OTHER RIFAMPICIN AND ITS SALTS	313.41	346.32	10.50
204	29419020	CEPHALEXIN AND ITS SALTS	187.37	162.87	-13.08
205	29419030	CIPROFLOXACINE AND ITS SALTS	58.60	30.31	-48.27
206	29419040	GENTAMYCIN AND ITS SALTS	44.03	44.11	0.17
207	29419050	NEOMYCIN	16.36	18.25	11.57
208	29419060	NORFLOXACIN AND ITS SALTS	71.76	36.45	-49.21
209	29419090	OTHER ANTIBIOTICS	4,255.24	4,486.00	5.42
210	29420011	CEFADROXIL	11.71	8.35	-28.66
211	29420012	IBUPROFANE	36.43	47.00	28.99
212	29420013	NIFEDIPINE	0.08	0.82	900.27
213	29420014	RANITIDINE	0.96	1.61	68.23
214	29420015	DANES SALT OF D (-) PHENYL GLYCINE	114.60	107.80	-5.93
215	29420016	D(-) PARA HYDROXY DANES SALTS	147.66	120.43	-18.45
216	29420021	TIMOLOL MALEATE	2.60	1.17	-55.04
217	29420022	TERBUTOLINE SULPHATE		0.20	
218	29420023	D(-) PHENYL GLYCIN CHLORIDE HCL (DPGCH)		0.32	
220	29420025	AMITRYPTYLINE HCL	0.24		
221	29420026	CYSTEANUNE HCL	15.52	21.93	41.38

222	29420027	ATENOLOL, PROPRONALOL	8.49	7.65	-9.85
224	29420032	CIMETIDINE	4.60	2.73	-40.76
225	29420033	OXYCLOZANIDE	0.07		
226	29420034	FAMOTIDINE	1.70	2.79	64.30
227	29420090	OTHER DILOXANIDE FUROATE, CIMETIDINE, FAMOTIDINE NES	1,796.54	1,855.71	3.29
229	30034900	OTHER	0.07	0.20	164.28
232	30044200	CONTAINING PSEUDOEPHEDRINE (INN) OR ITS SALTS		1.76	
234	30044910	ATROPIN AND SALTS THEREOF	0.01	0.59	5,584.55
238	30044960	BROMOHEXIN AND SOLBUTAMOL	0.04	0.07	66.77
239	30044970	THEOPHYLLINE AND SALTS THEREOF		0.02	
240	30044990	OTHER	64.17	44.92	-29.99
241	96020030	GELATIN CAPSULES,EMPTY	28.09	25.90	-7.82
		India's Total Import of BULK DRUGS	25743.35	25629.31	-0.44



BULK DRUG MANUFACTURERS ASSOCIATION OF INDIA

E-Marketing Portal for

Indian Bulk Drugs

www.bdmaiem.in

One Platform, Infinite Possibilities

**A one-stop Platform to Showcase & Source
APIs & Intermediates, Pallets, Impurities, CDMOs & CRAMS, Consultancy
& Analytical Services, Vendors – Chemicals /Equipment / Packing and
More!**

Key Features:

- ❖ **Smart Search** – Find by product, company, CAS number, or HS code
- ❖ **Direct Enquiry System** – Contact suppliers instantly through the portal
- ❖ **Verified Indian Manufacturers** – Reliable, quality-focused companies
- ❖ **Vendor & Service Provider Listings** – Expand your network and reach buyers
- ❖ **Domestic & International Reach** - Promoting make in India Pharma globally

**Join the Portal and Support BDMAI's mission to strengthen
India's Bulk Drug Industry**

Reach us at:

C-25, Industrial Estate, Sanathnagar, Hyderabad
www.bdmai.org; info@bdmai.org; ed@bdmai.org;
91-40-23706718/4804